Candel therapeutics r&d day presentations spotlight its advanced pipeline and capabilities to develop novel viral immunotherapies for patients with cancer

Needham, mass., dec. 06, 2022 (globe newswire) -- candel therapeutics, inc. (“candel” or “the company”) (nasdaq: cadl), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today held its research and development day to provide an extensive overview of the company's unique viral immunotherapy platforms and to review updated clinical data from its oncology-focused pipeline.
CADL Ratings Summary
CADL Quant Ranking